Acceleron (XLRN) option implied volatility flat into Phase III Believe results

Acceleron Pharma (NASDAQ: XLRN) July call option implied volatility is at 62, August is at 56; compared to its 52-week range of 37 to 152 into announcing with its partner Celgene (CELG) positive Phase III Believe results for luspatercept in transfusion dependent beta thalassemia.

You May Also Be Interested In

• Novo Nordisk (NVO) call put ratio 1.8 calls to 1 put into hosting its Capital Markets Day
• SpaceX (SPCX) call put ratio 1 call to 1 put amid wide price movement
• On Holding AG (ONON) call put ratio 4.7 calls to 1 put into analyst day